17 studies found for:    INFLAMMATORY BOWEL DISEASE 10
Show Display Options
Rank Status Study
1 Completed NIH Substudy for a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of Two Single IV Infusions of AIN457 10 mg/kg (Anti IL-17 Monoclonal Antibody) in Pts...
Conditions: Colitis;   Crohn's Disease;   Inflammatory Bowel Disease
Interventions: Drug: 100,838 AIN 457;   Drug: Anti-IL 17 Monoclonal Antibody;   Procedure: Colonoscopy;   Procedure: Infusion
2 Unknown  Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience
Condition: Pediatric Inflammatory Bowel Disease
Intervention:
3 Active, not recruiting Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
Conditions: Iron Deficiency Anaemia;   Inflammatory Bowel Disease;   Crohn's Disease
Interventions: Drug: ST10-021;   Drug: Placebo Comparator
4 Active, not recruiting Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)
Conditions: Iron Deficiency Anaemia;   Inflammatory Bowel Disease;   Ulcerative Colitis
Interventions: Drug: ST10-021;   Drug: Placebo Comparator
5 Completed Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: 10% Metronidazole Ointment
6 Completed Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease
Condition: Perianal Crohns'
Intervention: Drug: Metronidazole
7 Completed CESA 5.10 Investigation to Compare the Efficacy and Safety of the Adacolumn® Apheresis Device in Patients With Active Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Device: Adacolumn®
8 Terminated
Has Results
A Study With Pentasa in Patients With Active Crohn's Disease
Condition: Crohn´s Disease
Interventions: Drug: Pentasa;   Drug: Placebo
9 Recruiting Crohn's Extent of Resection Trial
Conditions: Crohn's Disease;   Recurrence
Interventions: Procedure: Extended resection;   Procedure: Conventional resection
10 Completed Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: AIN457;   Drug: Placebo
11 Terminated Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Placebo;   Drug: BIBR 796 BS, 5 mg;   Drug: BIBR 796 BS, 20 mg
12 Completed A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: MDX-1100 (anti-CXCL10 human monoclonal antibody)
13 Completed A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Biological: sterile saline for injection;   Biological: MDX-1100
14 Completed A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis
Condition: Moderately Active Ulcerative Colitis
Interventions: Biological: AG011;   Other: Placebo
15 Completed Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer
Conditions: Colorectal Cancer;   Inflammation
Intervention: Dietary Supplement: fish oil encapsuled
16 Completed Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Conditions: Gastric Ulcers;   Duodenal Ulcers
Interventions: Drug: TAK-438;   Drug: Placebo;   Drug: Lansoprazole
17 Completed Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Conditions: Gastric Ulcers;   Duodenal Ulcers
Interventions: Drug: TAK-438;   Drug: Placebo;   Drug: Lansoprazole

Indicates status has not been verified in more than two years